Latest Accounting News

Macquarie Group Limited reported a 3% increase in profit for the half year ended 30 September 2025, driven by strong performances in asset management and capital advisory, while declaring a 35% franked interim dividend of $2.80 per share.

Finaccess Restauración, S.L. has secured acceptances exceeding 90% in its takeover bid for Restaurant Brands New Zealand, setting the stage for compulsory acquisition of remaining shares and imminent delisting.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its Milklab plant-based milk brand, while preparing for a significant convertible note maturity in 2027.

Clime Capital reports an unaudited pre-tax NTA of 78.55 cents per share and announces a December quarter dividend guidance of 1.35 cents, maintaining an active share buyback program.

Growthpoint Properties Australia kicks off FY26 with robust leasing activity, high occupancy rates, and a strategic $24 million industrial acquisition, maintaining its financial guidance and sustainability credentials.

National Australia Bank reported a 1% increase in underlying profit for FY25 with stable cash earnings and a steady fully franked dividend of 85 cents per share. The bank’s refreshed strategy shows early momentum despite rising credit impairment charges.

National Australia Bank reported a 1.2% revenue increase to $20.872 billion in FY25, while net profit dipped 2.9% to $6.759 billion. The bank highlighted progress in customer-centric strategy, technology modernization, and sustainability initiatives.

Santana Minerals has been granted a crucial 25-year mining permit for its Bendigo-Ophir Gold Project in New Zealand, paving the way for construction and gold production pending environmental approvals.

Nova Eye Medical reported a 20% year-on-year revenue increase in Q1 FY26, reaffirming its FY26 sales guidance and targeting breakeven EBITDA by June 2026 amid cautious commercial expansion.

4DMedical has responded to ASX queries over its FY2025 financial report, clarifying assumptions behind intangible asset valuations and addressing the auditor’s qualified opinion.

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.

Austin Engineering has lowered its FY26 revenue and EBIT forecasts due to challenges in key contracts and operational inefficiencies, while outlining strategic measures to restore profitability.